Compared with microarray analysis, mRNA sequencing (RNA-Seq) provides a more precise and complete snapshot of the transcriptome and enables the identification of novel transcripts, alternative splicing, and gene fusion events. RNA-Seq also provides an alternative and affordable approach for gene expression quantification and differential gene expression analysis among groups of samples. It is widely used in disease research, drug response research, pharmacokinetics, and personalized healthcare research.
Novogene offers complete solutions for transcriptome sequencing and RNA-Seq quantification using state-of-the-art Illumina NovaSeq and HiSeq platforms with paired-end 150 bp (PE 150) sequencing strategy. The longer read length ensures superior data quality and accurate sequence assembly. Our experienced bioinformaticians work closely with customers to provide standard and customized data analysis and publication ready results for species with and without a reference genome.
- Extensive experience with >100,000 samples successfully sequenced in over 7,600 completed projects and articles published on transcriptome sequencing results across different species.
- Unsurpassed data quality with a guaranteed Q30 score ≥80% that exceeds Illumina’s official guarantee.
- Comprehensive data analysis using widely accepted mainstream software and mature in-house pipeline to discover novel transcripts, differential expressions, and function annotations.
- Free, powerful Novofinder software that enables Novogene customers to easily access and visualize data analysis results and annotations through a user-friendly interface.